W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

Transparency Council

26 June, 2025

The Transparency Council meeting 27/2025 on 30 June 2025

20 June, 2025

Opinion of the Transparency Council – cetuximab

20 June, 2025

Position of the Transparency Council – PütterPro2

20 June, 2025

Position of the Transparency Council – PütterPro2

20 June, 2025

Position of the Transparency Council – Tagrisso (osimertinib)

20 June, 2025

Opinion of the Transparency Council – cetuximab

18 June, 2025

The Transparency Council meeting 26/2025 on 23 June 2025

17 June, 2025

Opinion of the Transparency Council – ipratropium bromide

16 June, 2025

Opinion of the Transparency Council – ipratropium bromide

16 June, 2025

Opinion of the Transparency Council – fenoterol hydrobromide + ipratropium bromide

16 June, 2025

Opinion of the Transparency Council – prednisone

16 June, 2025

Opinion of the Transparency Council – amiloridum + hydrochlorothiazidum

16 June, 2025

Opinion of the Transparency Council – leflunomide

16 June, 2025

Position of the Transparency Council – Synacthen, Synacthen Depot (tetracosactide)

16 June, 2025

Position of the Transparency Council – Edarabid (edarawon)

16 June, 2025

Position of the Transparency Council – Cibinqo (abrocitinib)

16 June, 2025

Position of the Transparency Council – Keytruda (pembrolizumab)

16 June, 2025

Position of the Transparency Council – Lynparza (olaparib)

16 June, 2025

Position of the Transparency Council – Imfinzi (durvalumab)

16 June, 2025

Communication of the meeting of Transparency Council No. 24/2025 on 9 June 2025

11 June, 2025

The Transparency Council meeting 25/2025 on 16 June 2025

05 June, 2025

Opinion of the Transparency Council – loratadine

05 June, 2025

Opinion of the Transparency Council – cetirizine

05 June, 2025

Opinion of the Transparency Council – levocetirizine dihydrochloride

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑